Kynurenic acid-d5
Based on 2 publication(s) in Google Scholar
Kynurenic acid-d5 is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 350820-13-2
- Formula: C10H2D5NO3
- Molecular Weight:194.20
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Kynurenic acid-d5
MoreAll iGluR Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
NMDA Receptor |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 350820-13-2
-
Unlabeled Cas 492-27-3
-
Appearance Solid
-
Molecular Weight 194.20
-
Formula C10H2D5NO3
-
Color White to off-white
-
SMILES
OC1=C([2H])C(C(O)=O)=NC2=C1C([2H])=C([2H])C([2H])=C2[2H]
-
Synonyms
Quinurenic acid-d5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Reprogramming of the kynurenine pathway impairs NAD+ homeostasis and mediates doxorubicin-induced cardiotoxicity in mice. [Abstract]2025 Dec 6:89:103957. PMID: 41389767 -
J Pharm Biomed Anal
Validation of a quantitative analysis method for tryptophan metabolites in asthmatic mice and bacteria using GC-MS/MS. [Abstract]2026 Sep 1:277:117511. PMID: 41990598
Solvent & Solubility
0.1 M NaOH : 12.5 mg/mL (64.37 mM; ultrasonic and adjust pH to 9 with NaOH)
DMSO : 9.09 mg/mL (46.81 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug 4;281(31):22021-8. [Content Brief]
[3]. Albuquerque EX, et al. Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013 Apr 15;85(8):1027-32. [Content Brief]
[4]. Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent Eur J Immunol. 2014;39(1):6-13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M NaOH | 1 mM | 5.1493 mL | 25.7467 mL | 51.4933 mL | 128.7333 mL |
| 5 mM | 1.0299 mL | 5.1493 mL | 10.2987 mL | 25.7467 mL | |
| 10 mM | 0.5149 mL | 2.5747 mL | 5.1493 mL | 12.8733 mL | |
| 15 mM | 0.3433 mL | 1.7164 mL | 3.4329 mL | 8.5822 mL | |
| 20 mM | 0.2575 mL | 1.2873 mL | 2.5747 mL | 6.4367 mL | |
| 25 mM | 0.2060 mL | 1.0299 mL | 2.0597 mL | 5.1493 mL | |
| 30 mM | 0.1716 mL | 0.8582 mL | 1.7164 mL | 4.2911 mL | |
| 40 mM | 0.1287 mL | 0.6437 mL | 1.2873 mL | 3.2183 mL | |
| 0.1 M NaOH | 50 mM | 0.1030 mL | 0.5149 mL | 1.0299 mL | 2.5747 mL |
| 60 mM | 0.0858 mL | 0.4291 mL | 0.8582 mL | 2.1456 mL |
Kynurenic acid-d5 Related Classifications
HY-100806S Related Classifications
Powered by Bioz